Company intelligence / Profile preview

Ikarus Holding

Clinton, New Jersey, United Statesdnb.com ↗

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Ikaria developed INOmax® (nitric oxide for inhalation), FDA-approved for hypoxic respiratory failure in term and near-term newborns. The company also advanced carbon monoxide and hydrogen sulfide therapies into early clinical trials. It merged with INO Therapeutics to form a leader in therapeutic gases for critical care before being acquired by Mallinckrodt.

Therapeutic areas: PulmonologyCardiovascularNephrology
Modalities: Small moleculeGas therapyDrug/device combination
Industry: Biotech

Partnerships

Lee's Pharmaceutical for China registration/commercialization

Beyond the preview

Go deeper on Ikarus Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ikarus Holding.

Explore the full profile